国际肿瘤学杂志››2016,Vol. 43››Issue (2): 106-.
李青, 卢颖, 张春影, 毛俊, 李连宏
出版日期:
2016-02-08发布日期:
2015-12-28LI Qing, LU Ying, ZHANG Chun-Ying, MAO Jun, LI Lian-Hong
Online:
2016-02-08Published:
2015-12-28摘要:高迁移率蛋白A2(HMGA2)是一种非组蛋白染色质相关蛋白,其AT钩结构能够特异性结合特定的DNA序列,主要功能是作为致癌基因和结构转录因子。HMGA2几乎在所有类型的恶性肿瘤中表达,与肿瘤的形成、发展以及不良预后密切相关。HMGA2在各个生物过程,包括细胞增殖、细胞周期、干细胞自我更新、上皮间质转化及DNA损伤修复中都起到了重要作用。深入研究高迁移率蛋白A2对肿瘤的影响及其作用机制具有重大意义。
李青, 卢颖, 张春影, 毛俊, 李连宏. 高迁移率蛋白A2在肿瘤中的表达及作用机制[J]. 国际肿瘤学杂志, 2016, 43(2): 106-.
LI Qing, LU Ying, ZHANG Chun-Ying, MAO Jun, LI Lian-Hong. Expression and functional mechanism of high mobility group A2 in neoplasm[J]. Journal of International Oncology, 2016, 43(2): 106-.
[1] Zha L, Zhang J, Tang W, et al. HMGA2 elicits EMT by activating the Wnt/βcatenin pathway in gastric cancer[J]. Dig Dis Sci, 2013, 58(3): 724733. DOI:10.1007/s1062001223996. [2] Kong DQ, Su GQ, Zha L, et al. Coexpression of HMGA2 and Oct4 predicts an unfavorable prognosis in human gastric cancer[J]. Med Oncol, 2014, 31(8): 130139. DOI:10.1007/s1203201401305. [3] Wang XC, Liu XY, Li AY, et al. Overexpression of HMGA2 promotes metastasis and impacts survival of colorectal cancers[J]. Clin Cancer Res, 2011, 17(8): 25702580. DOI:10.1158/10780432.CCR102542. [4] Wu Y, Song Y, Liu H. Expression and its clinical significance of HMGA2 in the patients with nonsmall cell lung cancer[J]. Zhongguo Fei Ai Za Zhi, 2008, 11(3): 377381. DOI:10.3779/j.issn.10093419.2008.03.005. [5] Di Cello F, Hillion J, Hristov A, et al. HMGA2 participates in transformation in human lung cancer[J]. Mol Cancer Res, 2008, 6(5): 743750. DOI:10.1158/15417786.MCR070095. [6] Kumar MS, ArmenterosMonterroso E, East P, et al. HMGA2 functions as a competing endogenous RNA to promote lung cancer progression[J]. Nature, 2014, 505(7482): 212217. DOI:10.1038/nature12785. [7] Califano D, Pignata S, Losito NS, et al. High HMGA2 expression and high body mass index negatively affect the prognosis of patients with ovarian cancer[J]. J Cell Physiol, 2014, 229(1): 5359. DOI:10.1002/jcp.24416. [8] Malek A, Bakhidze E, Noske A, et al. HMGA2 gene is a promising target for ovarian cancer silencing therapy[J]. Int J Cancer, 2008, 123(2): 348356. DOI:10.1002/ijc.23491. [9] Morishita A, Zaidi MR, Mitoro AA, et al. HMGA2 is a driver of tumor metastasis[J]. Cancer Res, 2013, 73(14): 42894299. DOI:10.1158/00085472.CAN123848. [10] Sun M, Song CX, Huang H, et al. HMGA2/TET1/HOXA9 signaling pathway regulates breast cancer growth and metastasis[J]. Proc Natl Acad Sci USA, 2013, 110(24): 99209925. DOI:10.1073/pnas.1305172110. [11] Yang GL, Zhang LH, Bo JJ, et al. Overexpression of HMGA2 in bladder cancer and its association with clinicopathologic features and prognosis[J]. Eur J Surg Oncol, 2011, 37(3): 265271. [12] Liu B, Pang B, Hou XZ, et al. Expression of highmobility group AThook protein 2 and its prognostic significance in malignant gliomas[J]. Hum Pathol, 2014, 45(8): 17521758. DOI:10.1016/j.humpath.2014.02.028. [13] Yamazaki H, Mori T, Yazawa M, et al. Stem cell selfrenewal factors Bmi1 and HMGA2 in head and neck squamous cell carcinoma: clues for diagnosis[J]. Lab Invest, 2013, 93(12): 13311338. DOI:10.1038/labinvest.2013.120. [14] Thuault S, Tan EJ, Peinado H, et al. HMGA2 and smads coregulate SNAIL1 expression during induction of EpithelialtoMesenchymal transition[J]. J Biol Chem, 2008, 283(48): 3343733446. DOI:10.1074/jbc.M802016200. [15] Li Y, Zhao ZX, Xu CH, et al. HMGA2 induces transcription factor Slug expression to promote epithelialtomesenchymal transition and contributes to colon cancer progression[J]. Cancer Lett, 2014, 355(1): 130140. DOI:10.1016/j.canlet.2014.09.007. [16] Ikeda K, Ogawa K, Takeishi Y. The role of HMGA2 in the proliferation and expansion of a hematopoietic cell in myeloproliferative neoplasms[J]. Fukushima J Med Sci, 2012, 58(2): 91100. [17] Morshedi A, Ren ZL, Li JM, et al. Probing into the biological processes influenced by ESC factor and oncoprotein HMGA2 using iPSCs[J]. Stem Cell Rev, 2013, 9(4): 514522. DOI:10.1007/s1201501293738. [18] Nishino J, Kim I, Chada K, et al. Hmga2 promotes neural stem cell selfrenewal in young but not old mice by reducing p16Ink4a and p19Arf expression[J]. Cell, 2008, 135(2): 227239. DOI:10.1016/j.cell.2008.09.017. [19] Fedele M, Visone R, De Martino I, et al. HMGA2 induces pituitary tumorigenesis by enhancing E2F1 activity[J]. Cancer Cell, 2006, 9(6): 459471. DOI:10.1016/j.ccr.2006.04.024. [20] De Martino I, Visone R, Wierinckx A, et al. HMGA proteins upregulate CCNB2 gene in mouse and human pituitary adenomas[J]. Cancer Res, 2009, 69(5): 18441850. DOI:10.1158/00085472.CAN084133. [21] Tessari MA, Gostissa M, Altamura S, et al. Transcriptional activation of the cyclin A gene by the architectural transcription factor HMGA2[J]. Mol Cell Biol, 2003, 23(24): 91049116. DOI:10.1128/MCB.23.24.91049116.2003. [22] Yu HJ, Lim HH, Tjokro NO, et al. Chaperoning HMGA2 protein protects stalled replication forks in stem and cancer cells[J]. Cell Rep, 2014, 6(4): 684697. DOI:10.1016/j.celrep.2014.01.014. [23] Li AY, Boo LM, Wang SY, et al. Suppression of nonhomologous end joining repair by overexpression of HMGA2[J]. Cancer Res, 2009, 69(14): 56995706. DOI:10.1158/00085472.CAN084833. [24] Borrmann L, Schwanbeck R, Heyduk T, et al. High mobility group A2 protein and its derivatives bind a specific region of the promoter of DNA repair gene ERCC1 and modulate its activity[J]. Nucleic Acids Res, 2003, 31(23): 68416851. DOI:10.1093/nar/gkg884. [25] Natarajan S, HombachKlonisch S, Droege PA. HMGA2 inhibits apoptosis through interaction with ATRCHK1 signaling complex in human cancer cells[J]. Neoplasia, 2013, 15(3): 263. DOI:10.1593/neo.121988. |
[1] | 刘娜, 寇介丽, 杨枫, 刘桃桃, 李丹萍, 韩君蕊, 杨立洲.血清miR-106b-5p、miR-760联合低剂量螺旋CT诊断早期肺癌的临床价值[J]. 国际肿瘤学杂志, 2024, 51(6): 321-325. |
[2] | 杨蜜, 别俊, 张加勇, 邓佳秀, 唐组阁, 卢俊.局部晚期可切除食管癌新辅助治疗疗效及预后分析[J]. 国际肿瘤学杂志, 2024, 51(6): 332-337. |
[3] | 袁健, 黄燕华.Hp-IgG抗体联合血清DKK1、sB7-H3对早期胃癌的诊断价值[J]. 国际肿瘤学杂志, 2024, 51(6): 338-343. |
[4] | 陈红健, 张素青.血清miR-24-3p、H2AFX与肝癌患者临床病理特征及术后复发的关系研究[J]. 国际肿瘤学杂志, 2024, 51(6): 344-349. |
[5] | 郭泽浩, 张俊旺.PFDN及其亚基在肿瘤发生发展中的作用[J]. 国际肿瘤学杂志, 2024, 51(6): 350-353. |
[6] | 张百红, 岳红云.新作用机制的抗肿瘤药物进展[J]. 国际肿瘤学杂志, 2024, 51(6): 354-358. |
[7] | 许凤琳, 吴刚.EBV在鼻咽癌肿瘤免疫微环境和免疫治疗中的研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 359-363. |
[8] | 王盈, 刘楠, 郭兵.抗体药物偶联物在转移性乳腺癌治疗中的研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 364-369. |
[9] | 张蕊, 褚衍六.基于FIT与肠道菌群的结直肠癌风险评估模型的研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 370-375. |
[10] | 高凡, 王萍, 杜超, 褚衍六.肠道菌群与结直肠癌非手术治疗的相关研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 376-381. |
[11] | 王丽, 刘志华, 杨伟洪, 蒋凤莲, 李全泳, 宋浩杰, 鞠文东.ROS1突变肺腺鳞癌合并脑梗死为主要表现的Trousseau综合征1例[J]. 国际肿瘤学杂志, 2024, 51(6): 382-384. |
[12] | 刘静, 刘芹, 黄梅.基于SMOTE算法的食管癌放化疗患者肺部感染的预后模型构建[J]. 国际肿瘤学杂志, 2024, 51(5): 267-273. |
[13] | 杨琳, 路宁, 温华, 张明鑫, 朱琳.炎症负荷指数与胃癌临床关系研究[J]. 国际肿瘤学杂志, 2024, 51(5): 274-279. |
[14] | 王俊毅, 洪楷彬, 纪荣佳, 陈大朝.癌结节对结直肠癌根治性切除术后肝转移的影响[J]. 国际肿瘤学杂志, 2024, 51(5): 280-285. |
[15] | 张宁宁, 杨哲, 檀丽梅, 李振宁, 王迪, 魏永志.宫颈细胞DNA倍体分析联合B7-H4和PKCδ对宫颈癌的诊断价值[J]. 国际肿瘤学杂志, 2024, 51(5): 286-291. |
阅读次数 | ||||||
全文 |
|
|||||
摘要 |
|
|||||